Article Impact Level: HIGH Data Quality: STRONG Summary of Cochrane Database of Systematic Reviews https://doi.org/10.1002/14651858.CD014808.pub2 Dr. Fahim Ebrahimi et al.
Points
- A Cochrane review of 12 trials showed low-dose colchicine reduced recurrent heart attacks and strokes in cardiovascular disease patients.
- For every 1,000 treated patients, colchicine prevented nine heart attacks and eight strokes, demonstrating a clinically significant impact.
- While no increase in serious adverse events was observed, mild gastrointestinal side effects were more common with colchicine use.
- Colchicine, an inexpensive anti-inflammatory drug, offers a promising, accessible option for secondary prevention in high-risk patients.
- Further research is needed to clarify colchicine’s effects on overall mortality, revascularization procedures, and patient quality of life.
Summary
This Cochrane systematic review synthesized data from 12 randomized controlled trials, involving nearly 23,000 individuals with a history of cardiovascular disease (CVD), myocardial infarction, or stroke, to evaluate the benefits and harms of low-dose colchicine for secondary prevention. Participants, predominantly male (~80%) with a mean age ranging from 57 to 74 years, received either 0.5 mg of colchicine once or twice daily for at least six months or a placebo/usual care. The primary outcomes assessed included all-cause mortality, myocardial infarction, and serious adverse events.
The review found that low-dose colchicine significantly reduced the incidence of recurrent cardiovascular events. Specifically, for every 1,000 individuals treated, there were nine fewer heart attacks and eight fewer strokes compared to the control groups. This translates to an approximate prevention of two heart attacks and two strokes among 200 people with CVD who would typically experience seven heart attacks and four strokes. While the review identified no increase in serious adverse events, patients taking colchicine experienced a higher incidence of mild and transient gastrointestinal side effects.
Despite the promising reductions in myocardial infarction and stroke, the evidence regarding colchicine’s effect on overall death rates, the need for coronary revascularization procedures (PCI/CABG), quality of life, or hospitalization duration remained unclear. The authors emphasize the need for further research in these areas. Nevertheless, given its anti-inflammatory properties and established safety profile at low doses, colchicine presents an inexpensive and accessible repurposing opportunity for the secondary prevention of cardiovascular events in high-risk patients.
Link to the article: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014808.pub2/full
References
Ebrahimi, F., Ebrahimi, R., Beer, M., Schönenberger, C. M., Ewald, H., Briel, M., Janiaud, P., Hirt, J., & Hemkens, L. G. (2025). Colchicine for the secondary prevention of cardiovascular events. Cochrane Database of Systematic Reviews, 2025(11). https://doi.org/10.1002/14651858.CD014808.pub2
